Medscape: AFIRE encourages less antiplatelet use with novel oral anticoagulant for atrial fibrillation treatment

Medscape turned to the expertise of Richard Becker, MD, Director, UC Heart, Lung and Vascular Institute, when reporting the results of a randomized trial comparing an oral anticoagulation with an antiplatelet agent versus an oral anticoagulation alone in patients with both atrial fibrillation and stable coronary artery disease. Becker, also director of the UC Division of Cardiovascular Health and Disease in the College of Medicine and a UC Health cardiologist, authored a New England Journal of Medicine editorial on the results of the AFIRE trial.